

# Human PCSK9 Monoclonal Antibody, Endotoxin 0.05 EU/mg

Catalog No.: YR0155

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<0.05EU/mg (<0.00005EU/μg)  
Determined by LAL gel clotting assay

### Sterility

0.2 μm filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

What is evolocumab biosimilar research grade? Evolocumab (trade name Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. The PCSK9 protein targets LDL receptors for degradation. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in turn preventing PCSK9-mediated LDLR degradation and permitting the LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels. Evolocumab biosimilar uses the same protein sequences as the therapeutic antibody evolocumab.

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Evolocumab Biosimilar

### Isotype

Human IgG2 lambda

### Immunogen

Human PCSK9

### Recommended Isotype Control(s)

### Recommended Dilution Buffer

1×PBS pH 7.0

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Production

Purified from cell culture supernatant in an animal-free facility

### Purification

Protein A or G purification

### Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)